Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Pelt – page 41

870 clinical trials in Pelt, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Pelt at a glance
870
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

870 trials in Pelt

Open in trial search

Asthma

Not recruiting

Study on the Effects of Atuliflapon in Adults with Moderate to Severe Uncontrolled Asthma

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Atuliflapon
  • Sponsor:AstraZeneca AB

Migraine+3

Not recruiting

Study Comparing Atogepant and Topiramate for Preventive Treatment in Adults with Migraine

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Obicetrapib
  • Sponsor:NewAmsterdam Pharma B.V.

Breast cancer

Not recruiting

Study of Pembrolizumab and Chemotherapy for Patients with HR+/HER2- Advanced Breast Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Gout

Not recruiting

Study on the Effects of Tigulixostat and Allopurinol in Patients with Gout and High Uric Acid Levels

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:LG Chem Ltd.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative

Not recruiting

Study on the Effects of Eclitasertib in Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Eclitasertib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Endometriosis

Not recruiting

Study on the Effectiveness and Safety of OG-6219 and Naproxen Sodium for Women Aged 18-49 with Moderate to Severe Endometriosis Pain

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:FOR-6219
  • Sponsor:Organon LLC

Bladder cancer

Not recruiting

Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Hypertriglyceridaemia+1

Not recruiting

Study of Olezarsen (ISIS 678354) for Patients with High Triglycerides and Heart Disease or Severe High Triglycerides

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Pelt

What the registry says about research in the country

01 Multiple Sclerosis Research

Extensive research focusing on relapsing forms of multiple sclerosis, evaluating novel therapeutic approaches and comparing treatment efficacies. Studies investigate various medications including frexalimab and remibrutinib against established treatments.

  • Relapsing MS Therapies
  • Disease Progression Analysis
  • Treatment Comparison Studies

Several trials aim to assess reduction in relapse frequency and improvement in patient outcomes.

02 Progressive MS Studies

Dedicated research into primary progressive multiple sclerosis (PPMS) and secondary progressive forms, exploring innovative treatments and their impact on disease progression. Studies evaluate higher-dose protocols and long-term effectiveness.

  • Disability Progression Markers
  • Novel Treatment Approaches
  • Long-term Safety Assessments

Focus on developing treatments to delay disability progression and improve patient mobility.

03 Advanced Therapeutic Studies

Investigation of innovative treatment modalities including BTK inhibitors and combination therapies. Research includes assessment of brain remyelination and neurodegeneration markers.

  • Biomarker Analysis
  • Pharmacokinetic Studies
  • Safety Monitoring

Comprehensive evaluation of new therapeutic approaches using advanced imaging and clinical assessments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.